摘要
目的:观察低分子肝素钙辅助治疗原发性肾病综合征的临床疗效。方法:选取我院及新桥医院自2005年9月至2010年9月收治的110例原发性肾病综合征患者随机分为观察组(低分子肝素钙辅助治疗组)和对照组(常规治疗组)各55例,比较两组患者的临床疗效。结果:两组患者总有效率比较差异显著(X2=12.365,P<0.01),治疗后尿蛋白、ALB、FIB比较有显著差异(P<0.01),具有统计学意义。结论:低分子肝素钙可显著改善肾病综合征的高凝状态、提高治疗效果,值得推广应用。
Objective： To observe the clinical efficacy of low molecular weight heparin on primary nephrotic syndrome.Method： In our hospital from Sep.2005 to Sep.2010,110 cases of primary nephrotic syndrome were randomly divided into two groups（low molecular weight heparin adjuvant therapy group） and control group（conventional therapy group）,each with 55 cases,the clinical efficacy of two groups were compared.Result： The total effective two groups were significantly different（X2= 12.365,P 0.01）,after treatment,There was a significant difference in urinary protein,ALB,FIB（P 0.01）,There＇s statistical significance.Conclusion： The low molecular weight heparin can significantly improve the hypercoagulable state of nephrotic syndrome,improve treatment,should be widely applied.
出处
《河北医学》
CAS
2013年第10期1511-1513,共3页
Hebei Medicine
关键词
低分子肝素钙
肾病综合征
高凝状态
Low molecular weight heparin
Nephrotic syndrome
Hypercoagulable state
